Hepatitis C viral load, genotype 3 and interleukin-28B CC genotype predict mortality in HIV and hepatitis C-coinfected individuals

被引:18
|
作者
Clausen, Louise Nygaard [1 ,3 ,4 ]
Astvad, Karen [2 ]
Ladelund, Steen [3 ]
Larsen, Mette Vang
Schonning, Kristian [2 ]
Benfield, Thomas [3 ]
机构
[1] Copenhagen Univ Hosp, Copenhagen Hepatitis C Program CO HEP, Dept Infect Dis, DK-2650 Hvidovre, Denmark
[2] Copenhagen Univ Hosp, Dept Clin Microbiol, DK-2650 Hvidovre, Denmark
[3] Copenhagen Univ Hosp, Clin Res Ctr, DK-2650 Hvidovre, Denmark
[4] Univ Copenhagen, Fac Hlth Sci, Dept Int Hlth Immunol & Microbiol, Copenhagen, Denmark
基金
英国医学研究理事会;
关键词
chronic inflammation; disease burden; HIV exposure group; time-updated survival analysis; IMMUNODEFICIENCY-VIRUS-INFECTION; INJECTION-DRUG USERS; STAGE LIVER-DISEASE; NATURAL-HISTORY; HEMOPHILIC PATIENTS; HCV GENOTYPE; PROGRESSION; IMPACT; COHORT; ASSOCIATION;
D O I
10.1097/QAD.0b013e3283553581
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: We hypothesized that hepatitis C virus (HCV) load and genotype may influence all-cause mortality in HIV-HCV-coinfected individuals. Design and methods: Observational prospective cohort study. Mortality rates were compared in a time-updated multivariate Poisson regression analysis. Results: We included 264 consecutive HIV-HCV-coinfected individuals. During 1143 person years at risk (PYR) 118 individuals died [overall mortality rate 10 (95% confidence interval; 8, 12)/100 PYR]. In multivariate analysis, a 1 log increase in HCV viral load was associated with a 30% higher mortality risk [adjusted mortality rate ratio (aMRR): 1.30 (1.10,1.54)] when adjusted for sex, age, HIV exposure group, CD4 cell count, HIV RNA, HCV genotype and interleukin (IL)-28B genotype. Further, HCV genotype 3 vs. 1 [aMRR: 1.83 (1.12, 2.98)] and HIV RNA [aMRR: 3.14 (1.37,7.17) for undetectable vs. just detectable HIV RNA] were independent predictors of mortality, whereas a higher CD4 cell count was associated with a 41% reduction in mortality rate per 50 cell increase between 0 and 200 cells/mu l [aMRR: 0.59 (0.48, 0.72)] and a 10% reduction for increases above 200 cells/mu l [aMRR: 0.90 (0.82-0.98)]. IL28B) CC genotype was associated with 54% higher mortality risk [aMRR: 1.54 (0.89, 3.82] compared to TT genotype. Conclusion: High-HCV viral load, HCV genotype 3 and IL28B genotype CC had a significant influence on the risk of all-cause mortality among individuals coinfected with HIV-1. This may have consequences for the management of HIV-HCV-coinfected individuals. (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
引用
收藏
页码:1509 / 1516
页数:8
相关论文
共 50 条
  • [1] HEPATITIS C VIRAL LOAD AND GENOTYPE 3 PREDICT ALL-CAUSE MORTALITY IN HEPATITIS C AND HIV CO-INFECTED INDIVIDUALS
    Clausen, Louise N.
    Astvad, Karen
    Ladelund, Steen
    Larsen, Mette V.
    Schonning, Kristian
    Benfield, Thomas
    HEPATOLOGY, 2011, 54 : 1188A - 1188A
  • [2] Observed and Calculated Interleukin-28B Genotype Frequencies in Hepatitis C Virus Infection
    Lindh, Magnus
    Lagging, Martin
    Norkrans, Gunnar
    Hellstrand, Kristoffer
    HEPATOLOGY, 2010, 52 (05) : 1860 - 1861
  • [3] Association of Interleukin-28B and Hepatitis C Genotype 1 with a High Viral Load and Response to Pegylated Interferon plus Ribavirin Therapy
    Takita, Masahiro
    Hagiwara, Satoru
    Arizumi, Tadaaki
    Hayaishi, Sousuke
    Ueda, Taisuke
    Kitai, Satoshi
    Yada, Norihisa
    Inoue, Tatsuo
    Minami, Yasunori
    Chung, Hobyung
    Ueshima, Kazuomi
    Sakurai, Toshiharu
    Kudo, Masatoshi
    DIGESTION, 2011, 84 : 56 - 61
  • [4] Association of Overt Diabetes Mellitus with the Non-CC but not the CC Genotype of Interleukin-28B in Hepatitis C Virus Infected Patients
    Kumar, Ashish
    Gupta, Varun
    Sharma, Praveen
    Bansal, Naresh
    Singla, Vikas
    Arora, Anil
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2016, 4 (01) : 26 - 31
  • [5] Association of Interleukin-28B Genotype and Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C
    Hodo, Yuji
    Honda, Masao
    Tanaka, Akihiro
    Nomura, Yoshimoto
    Arai, Kuniaki
    Yamashita, Taro
    Sakai, Yoshio
    Yamashita, Tatsuya
    Mizukoshi, Eishiro
    Sakai, Akito
    Sasaki, Motoko
    Nakanuma, Yasuni
    Moriyama, Mitsuhiko
    Kaneko, Shuichi
    CLINICAL CANCER RESEARCH, 2013, 19 (07) : 1827 - 1837
  • [6] Observed and Calculated Interleukin-28B Genotype Frequencies in Hepatitis C Virus Infection Reply
    Antonio Montes-Cano, Marco
    Raul Garcia-Lozano, Jose
    Abad-Molina, Cristina
    Romero-Gomez, Manuel
    Barroso, Natalia
    Aguilar-Reina, Jose
    Nunez-Roldan, Antonio
    Francisca Gonzalez-Escribano, Maria
    HEPATOLOGY, 2010, 52 (05) : 1861 - 1862
  • [7] Linkage of the Hepatitis C Virus Genotype and Interleukin-28B Genetic Polymorphisms in Asian Patients
    Huang, Chung-Feng
    Dai, Chia-Yen
    Huang, Jee-Fu
    Chuang, Wan-Long
    Yu, Ming-Lung
    HEPATOLOGY, 2011, 53 (01) : 367 - 368
  • [8] Impact of interleukin-28B genotype on in vitro and in vivo systems of hepatitis C virus replication
    Chayama, Kazuaki
    Hayes, C. Nelson
    Imamura, Michio
    HEPATOLOGY RESEARCH, 2012, 42 (09) : 841 - 853
  • [9] Early viral load and recipient interleukin-28B rs12979860 genotype are predictors of the progression of hepatitis C after liver transplantation
    Graziadei, Ivo W.
    Zoller, Heinz M.
    Schloegl, Anna
    Nachbaur, Karin
    Pfeiffer, Karl-Peter
    Mark, Walter
    Mikuz, Gregor
    Pratschke, Johann
    Margreiter, Raimund
    Vogel, Wolfgang
    LIVER TRANSPLANTATION, 2012, 18 (06) : 671 - 679
  • [10] Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype
    Neukam, K.
    Nattermann, J.
    Rallon, N.
    Rivero, A.
    Caruz, A.
    Macias, J.
    Vogel, M.
    Benito, J. M.
    Camacho, A.
    Mira, J. A.
    Schwarze-Zander, C.
    Barreiro, P.
    Martinez, A.
    Rockstroh, J. K.
    Soriano, V.
    Pineda, J. A.
    HIV MEDICINE, 2011, 12 (08) : 487 - 493